Workflow
股份配售
icon
Search documents
永恒策略(00764)拟配售最多2000万股 净筹约1960万港元
智通财经网· 2025-12-17 12:10
智通财经APP讯,永恒策略(00764)发布公告,于2025年12月17日,公司拟配售最多2000万股,相当于公 司经配发及发行配售股份扩大后的已发行股本约4.96%。配售价为每股配售股份1.00港元。假设根据配 售协议配售配售股份最高数目,配售事项所得款项总额将为2000万港元,而所得款项净额将约为1960万 港元。公司拟将所得款项净额用于偿还集团债务及一般营运资金。 ...
永恒策略(00764.HK)拟配售最多2000万股 净筹1960万港元
Ge Long Hui· 2025-12-17 12:09
假设根据配售协议配售配售股份最高数目,配售事项所得款项总额将为2000万港元,而所得款项净额将 约为1960万港元(经扣除配售事项之佣金及其他开支)。公司拟将所得款项净额用于偿还集团债务及一般 营运资金。 格隆汇12月17日丨永恒策略(00764.HK)公告,于2025年12月17日,公司与配售代理订立配售协议,据 此,公司有条件同意透过配售代理按竭尽所能基准按配售价为每股配售股份1.00港元向不少于六名承配 人配售最多2000万股配售股份,而彼等及彼等之最终实益拥有人均为独立第三方。 ...
高山企业拟折让约10.45%配售最多 6700万股配售股份
Zhi Tong Cai Jing· 2025-12-16 10:04
Core Viewpoint - The company, Gao Shan Enterprises (00616), has announced a conditional placement of up to 67 million shares at a price of HKD 0.30 per share, which represents a discount to the market price on the date of the agreement [1][2]. Group 1: Share Placement Details - The maximum number of shares to be placed represents approximately 4.03% of the company's issued share capital as of the announcement date, and about 3.87% assuming all placement shares are issued [1]. - The placement price of HKD 0.30 per share is approximately 10.45% lower than the closing price of HKD 0.335 on December 16, 2025, and about 10.98% lower than the average closing price of HKD 0.337 over the preceding five trading days [1]. - The expected total gross proceeds from the placement, after deducting commissions and related costs, are approximately HKD 20.10 million, with a net amount of about HKD 19.89 million [1]. Group 2: Use of Proceeds - The net proceeds from the placement, estimated at approximately HKD 0.297 per share, will be used to cover additional construction costs for the Fenghua project located at 646, 648, and 648A Castle Peak Road, Kowloon [2]. - The total area of the site for the Fenghua project is approximately 9,206 square feet, and the development plan has been adjusted to convert it into student dormitories due to current market conditions [2].
亿华通(02402.HK)拟配售最多888万股新H股 总筹2.01亿港元
Ge Long Hui A P P· 2025-12-15 22:53
公司将自配售事项收取的所得款项总额及所得款项净额估计分别约为2.014亿港元及1.977亿港元。配售 事项的所得款项净额将按以下方式及比例动用:90%用于偿还银行贷款,本金总额约为5.31亿港元,当 中涉及53笔银行贷款,每笔贷款金额介乎约5.9万港元至约1.28亿港元,到期日范围介乎2025年12月至 2026年9月期间;及10%用于集团的一般营运资金,包括集团的租金成本、员工开支、专业费用及其他 行政开支。 配售股份相当于公司于本公告日期已发行股本总数约3.83%。配售价每股H股22.68港元,较H股于12月 15日(即最后交易日及配售价厘定日期)在联交所所报的收市价每股26.68港元折让约14.99%。配售股份将 根据一般授权配发及发行。 格隆汇12月16日丨亿华通(02402.HK)发布公告,2025年12月16日,公司与配售代理(即国泰君安国际)订 立配售协议,据此,配售代理已有条件同意根据配售协议所载条款并在其条件规限下,按尽力基准促使 不少于六名承配人按配售价认购最多888万股新H股。 ...
鼎亿集团投资:配售115,000,000股普通股筹得约53.1百万港元净额并已全部动用
Jin Rong Jie· 2025-12-15 15:18
Group 1 - The core point of the article is that Dingyi Group Investment has provided supplementary disclosure regarding the use of proceeds from a placement completed between July and August 2024, raising approximately HKD 53.10 million [1] - The company placed 115,000,000 ordinary shares at a price of HKD 0.47 per share [1] - Of the net proceeds, HKD 31.86 million is allocated for investment opportunities, while HKD 21.24 million is designated for general working capital [1] - As of March 31, 2025, and the announcement date, the unutilized balance of proceeds is zero [1]
派格生物医药-B拟配售513.6万股 净筹约2.96亿港元
Group 1 - The company has entered into a placement agreement with joint placement agents to issue 5.136 million shares at a price of HKD 58.41 per share, targeting at least six subscribers [2] - The placement shares represent approximately 1.84% of the issued H shares and about 1.33% of the total issued shares as of the announcement date, and will account for approximately 1.81% of H shares and 1.31% of total shares post-issuance [2] Group 2 - The placement price of HKD 58.41 per share reflects a 10% discount compared to the closing price of HKD 64.90 per share on December 12, 2025 [3] - The estimated net proceeds from the placement are approximately HKD 296 million, with around 40% allocated for building a next-generation intelligent R&D and data platform, 28% for loan repayment and strengthening capital structure, 12% for ongoing and planned R&D of PB-2301 and PB-2309, 10% for establishing a subsidiary in Hong Kong and accelerating overseas business expansion, and 10% for general corporate purposes and working capital [3]
派格生物医药-B拟折让10%配售合共513.6万股配售股份 净筹约2.96亿港元
Zhi Tong Cai Jing· 2025-12-14 11:44
假设所有配售股份获悉数配售,配售的估计所得款项总额及所得款项净额(经扣除本公司将承担的相关 成本及开支后)将分别为约3亿港元及约2.96亿港元。其中:1.约40%,构建新一代智能化研发与数据平 台;2.约28%,偿还贷款及强化本公司资本结构;3.约12%,持续及计划研发PB-2301及PB-2309;4.约10%, 设立香港附属公司及加快本集团海外业务布局;5.约10%,一般公司用途及营运资金。 假设于本公告日期至完成日期期间本公司的已发行股本并无变动,513.6万股配售股份之总数相当于: (i)本公告日期已发行H股的约1.84%及已发行股份总数的约1.33%;及(ii)经配发及发行配售股份扩大的H 股的约1.81%及股份总数的约1.31%。配售价为每股配售股份58.41港元,较H股于2025年12月12日(香港 时间)(即配售协议日期)在联交所所报的收市价每股64.90港元折让10%。 派格生物医药-B(02565)发布公告,于2025年12月12日(交易时段后),本公司与联席配售代理订立配售协 议,据此,本公司已有条件同意透过联席配售代理按尽力基准以每股配售股份58.41港元的价格向不少 于六名承配人配售 ...
派格生物医药-B(02565)拟折让10%配售合共513.6万股配售股份 净筹约2.96亿港元
智通财经网· 2025-12-14 11:41
假设所有配售股份获悉数配售,配售的估计所得款项总额及所得款项净额(经扣除本公司将承担的相关 成本及开支后)将分别为约3亿港元及约2.96亿港元。其中:1.约40%,构建新一代智能化研发与数据平 台;2.约28%,偿还贷款及强化本公司资本结构;3.约12%,持续及计划研发PB-2301及 PB-2309;4.约10%, 设立香港附属公司及加快本集团海外业务布局;5.约10%,一般公司用途及营运资金。 智通财经APP讯,派格生物医药-B(02565)发布公告,于2025年12月12日(交易时段后),本公司与联席配 售代理订立配售协议,据此,本公司已有条件同意透过联席配售代理按尽力基准以每股配售股份58.41 港元的价格向不少于六名承配人配售合共513.6万股配售股份,该等配售股份将由本公司根据一般授权 按配售协议所载条款及条件发行。 假设于本公告日期至完成日期期间本公司的已发行股本并无变动,513.6万股配售股份之总数相当于: (i)本公告日期已发行H股的约1.84%及已发行股份总数的约1.33%;及(ii)经配发及发行配售股份扩大的H 股的约1.81%及股份总数的约1.31%。配售价为每股配售股份58.41港元 ...
心玮医疗-B(06609.HK)拟折价1.10%向张涵配售100万股内资股 净筹4325万港元
Ge Long Hui· 2025-12-12 14:49
认购事项所得款项总额为4500万港元。经扣除公司就认购事项应付的专业费用及其他费用后,认购事项 的全部所得款项净额约为4325万港元(相当于约人民币3926万元),即每股认购股份净价约为43.25港元。 该等所得款项净额拟分配作医疗器械行业的投资及并购机会,目前预计将于2028年12月31日前悉数动 用。 格隆汇12月12日丨心玮医疗-B(06609.HK)宣布,为进一步提升公司的整体竞争力、为集团经营活动筹集 额外资金及促进集团业务稳定发展,于2025年12月12日,董事会决议建议根据特别授权发行认购股份, 且公司与认购方(公司副总裁、首席财务官、首席运营官兼联席公司秘书张涵)订立认购协议,据此,公 司有条件同意配发及发行,而认购方有条件同意认购合共100万股内资股,认购价为45.00港元,较紧接 认购协议日期前的交易日联交所所报每股H股收市价(即45.50港元)折让约1.10%。 ...
福田股份(08196.HK)拟折让约9.09%配售最多910.5万股 净筹526万港元
Ge Long Hui· 2025-12-10 12:39
Group 1 - The company, Foton Motor (08196.HK), announced a placement agreement with a placement agent to issue up to 9,104,976 shares at a price of HKD 0.60 per share, which represents approximately 20% of the existing issued share capital as of the announcement date [1] - The placement price of HKD 0.60 per share reflects a discount of about 9.09% compared to the closing price of HKD 0.66 on the date of the agreement [1] - If all placement shares are fully subscribed, the maximum total proceeds from the placement will be approximately HKD 5.46 million, with a net amount of about HKD 5.26 million expected after deducting placement agent commissions and other expenses [1] Group 2 - The net proceeds from the placement are intended to be used for the company's general working capital and business development [1]